Sanofi Receives FDA Approval to Market Diabetes Treatment Soliqua
November 22 2016 - 3:44AM
Dow Jones News
By Inti Landauro
PARIS--Sanofi SA (SAN.FR) Tuesday said the U.S. Food and Drug
Administration has approved the sale of Soliqua, a new diabetes
treatment.
The authorization from the FDA will allow Sanofi to market the
new treatment in the U.S., and is part of the company's efforts to
offset an expected decline in revenue following the loss of patent
protection for its Lantus insulin treatment.
Soliqua is a combination of two drugs already on the market,
including Lantus. Sanofi says a single daily dose of the mix will
allow a patient to improve the control of glycemia level.
The FDA is the first regulator to approve the sale of
Soliqua.
The Paris-based company is one of the world's biggest makers of
diabetes drugs, though that part of the business is under pressure
from increasingly cost-conscious heath-care systems. The company
expects revenue from diabetes drugs to decline as competition
between insulin makers intensifies.
Write to Inti Landauro at inti.landauro@wsj.com
(END) Dow Jones Newswires
November 22, 2016 03:29 ET (08:29 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024
